Pfizer shares were down more than 1% Monday afternoon despite the pharmaceutical giant’s report Sunday of successful late-stage trial results for an experimental rheumatoid arthritis drug. The study showed tasocitinib reduced p…
With King in its fold, Pfizer — which makes Lyrica and Celebrex — believes it can build an industry-leading portfolio of pain relievers. Among King’s most appealing entrants in that market is the new Embeda, designed to preve…
There’s a new plot twist in the takeover battle between French pharmaceutical giant Sanofi-Aventis and U.S. drugmaker Genzyme. A regulatory filing made by Genzyme on Thursday claims Sanofi may be willing to go much higher than …
Global pharmaceutical sales are expected to grow by 5% to 7% in 2011, thanks to robust growth in emerging markets, especially China, as well as new innovative treatments, and despite patent expirations and budget pressures in t…
French pharmaceutical company Sanofi-Aventis announced a 10-year agreement with Covance on Thursday under which the Princeton, N.J.-based contract research firm will provide it with drug development services. Sanofi-Aventis wi…